StockLens

Biocon Limited (BIOCON) share price and analysis

BIOCON last traded at ₹359.40 (-0.77%) on the NSE. Market cap ₹58,861 Cr (Mid cap), Pharma & Healthcare sector.

Overall rating: 2.4/10 (Poor)

Long-term view: Avoid. Serious weaknesses in the business, the valuation or both. Trade bias (next few weeks): Strong short. Trend and momentum are clearly pointing down.

Strengths of BIOCON

Weaknesses of BIOCON

Key numbers

NumberValueAssessmentNormal range
P/E (TTM)120.6Expensive vs peers37.0–49.3 (sector median 41.1)
Forward P/E37.7Profits expected to growbelow today's P/E (120.6) and near 41
Price / book1.70Low2–6
EPS (TTM)₹2.98Profitableabove ₹0
Return on equity1.0%Weak15%+ (below 10% is weak)
Debt / equity0.42Low debtbelow 1.0 (under 0.5 is great)
Net margin2.6%Thin10%+ (below 5% is thin)
Operating margin9.1%Thin20%+ strong, below 10% thin
Revenue growth+2.2%Shrinking10%+ a year (below 3% is weak)
Profit growth-61.5%Falling10%+ a year (falling is weak)
Dividend yield0.14%Small payout1.5%+ (none is fine for growth firms)
Current ratio1.22Adequate1.5+ (below 1 is tight)
52W high₹447.1520% below · far from the highprice in the top 40% of its 52-week range
52W low₹318.40Price is 13% above it
50-DMA₹365.56Price 1.7% belowprice above it = short-term uptrend
200-DMA₹389.98Price 7.8% belowprice above it = long-term uptrend
1Y return-6.0%Lagged the Nifty 50Nifty 50 did −0.4%
Beta0.34Steadier than the market0.8–1.3 (1 = moves with market)
Promoter / insider48.2%Moderate stake50%+ shows owner commitment
Institutions33.4%Strong big-investor interest30%+ is strong
Analyst target₹411.8414.6% upside · 19 analysts8%+ upside

Questions about BIOCON

What is the share price of Biocon Limited (BIOCON) today?

BIOCON last traded at ₹359.40 (-0.77% on the day) on the NSE. Its 52-week range is ₹318.40 to ₹447.15. Prices are delayed and come from Yahoo Finance.

Is BIOCON a good stock for the long term?

StockLens rates BIOCON 2.4 out of 10 (Poor) overall. Its long-term verdict is "Avoid": Serious weaknesses in the business, the valuation or both. Strengths: low debt, analyst upside, positive momentum. Concerns: expensive vs peers, weak ROE, downtrend.

Is BIOCON share overvalued?

BIOCON trades at a P/E of 120.6 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Expensive vs peers". Its price-to-book ratio is 1.70.

Is BIOCON good for short-term trading?

The trade bias for the next few weeks is "Strong short": Trend and momentum are clearly pointing down. The price is 7.8% below its 200-day average and 14-day RSI is 50.

Which stocks are similar to BIOCON?

Similar Pharma & Healthcare stocks of comparable size include Alkem Laboratories, Glenmark Pharmaceuticals, Lupin, Max Healthcare, Aurobindo Pharma. You can compare up to 4 of them side by side on StockLens.

About Biocon Limited

Biocon Limited, together with its subsidiaries, manufactures biotechnology products and offers research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics; Biosimilars; and Contract Research, Development and Manufacturing Organization (CRDMO) segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, central nervous system, anti-cancer/oncology, multiple sclerosis, immunosuppressants, and specialty molecules; and biosimilars products for oncology, diabetes, and immunology therapeutic areas. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal health, consumer goods, and specialty chemical industries, as well as academic institutions, non-profit organizations, and government agencies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Stocks similar to BIOCON

Compare BIOCON with ALKEM, GLENMARK, LUPIN

Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.